Dynamic mass redistribution analysis of endogenous β-adrenergic receptor signaling in neonatal rat cardiac fibroblasts

Pharmacology Research and Perspectives

Volumn 2, Issue 1, 2014, Pages 1-16

  Carter, Rhonda L ^a   Grisanti, Laurel A ^a   Yu, Justine E ^a   Repas, Ashley A ^a   Woodall, Meryl ^a   Ibetti, Jessica ^a   Koch, Walter J ^a   Jacobson, Marlene A ^b   Tilley, Douglas G ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

Cardiac fibroblast; Dynamic mass redistribution; Epidermal growth factor receptor; Fluorescence resonance energy transfer; adrenergic receptor

Indexed keywords

BETA ADRENERGIC RECEPTOR; CATECHOLAMINE; CYCLIC AMP; DOBUTAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOPRENALINE; PROPRANOLOL; SALBUTAMOL; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL DENSITY; CELL ISOLATION; CONTROLLED STUDY; DYNAMIC MASS REDISTRIBUTION ANALYSIS; EC50; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE EXPRESSION; HEART FIBROBLAST; INTERNALIZATION; MAXIMUM DRUG EFFECT; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84925298521     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.24     Document Type: Article

References (51)

1. Allen MD, DiPilato LM, Rahdar M, Ren YR, Chong C, Liu JO, et al. (2006). Reading dynamic kinase activity in living cells for high-throughput screening. ACS Chem Biol 1: 371-376.
2. Azzi M, Pineyro G, Pontier S, Parent S, Ansanay H, Bouvier M (2001). Allosteric effects of G protein overexpression on the binding of beta-adrenergic ligands with distinct inverse efficacies. Mol Pharmacol 60: 999-1007.
3. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, et al. (2003). Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 100: 11406-11411.
4. Baker JG (2010). The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors. Br J Pharmacol 160: 1048-1061.
5. Boerrigter G, Lark MW, Whalen EJ, Soergel DG, Violin JD, Burnett, JC Jr (2011). Cardiorenal actions of TRV120027, a novel ss-arrestin-biased ligand at the angiotensin II type I receptor, in healthy and heart failure canines: a novel therapeutic strategy for acute heart failure. Circ Heart Fail 4: 770-778.
6. Cervantes D, Crosby C, Xiang Y (2010). Arrestin orchestrates crosstalk between G protein-coupled receptors to modulate the spatiotemporal activation of ERK MAPK. Circ Res 106: 79-88.
7. Chang FH, Bourne HR (1989). Cholera toxin induces cAMP-independent degradation of Gs. J Biol Chem 264: 5352-5357.
8. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M (1994). Inverse agonist activity of beta-adrenergic antagonists. Mol Pharmacol 45: 490-499.
9. Codd EE, Mabus JR, Murray BS, Zhang SP, Flores CM (2011). Dynamic mass redistribution as a means to measure and differentiate signaling via opioid and cannabinoid receptors. Assay Drug Dev Technol 9: 362-372.
10. Colombo F, Gosselin H, El-Helou V, Calderone A (2003). Beta-adrenergic receptor-mediated DNA synthesis in neonatal rat cardiac fibroblasts proceeds via a phosphatidylinositol 3-kinase dependent pathway refractory to the antiproliferative action of cyclic AMP. J Cell Physiol 195: 322-330.
11. De Arcangelis V, Liu S, Zhang D, Soto D, Xiang YK (2010). Equilibrium between adenylyl cyclase and phosphodiesterase patterns adrenergic agonist dose-dependent spatiotemporal cAMP/protein kinase A activities in cardiomyocytes. Mol Pharmacol 78: 340-349.
12. Deng H, Sun H, Fang Y (2013). Label-free cell phenotypic assessment of the biased agonism and efficacy of agonists at the endogenous muscarinic M receptors. J Pharmacol Toxicol Methods 68: 323-333.
13. D'Souza KM, Malhotra R, Philip JL, Staron ML, Theccanat T, Jeevanandam V, et al. (2011). G protein-coupled receptor kinase-2 is a novel regulator of collagen synthesis in adult human cardiac fibroblasts. J Biol Chem 286: 15507-15516.
14. Engelhardt S, Grimmer Y, Fan GH, Lohse MJ (2001). Constitutive activity of the human beta(1)-adrenergic receptor in beta(1)-receptor transgenic mice. Mol Pharmacol 60: 712-717.
15. Fang Y (2006). Label-free cell-based assays with optical biosensors in drug discovery. Assay Drug Dev Technol 4: 583-595.
16. Fang Y, Ferrie AM (2008). Label-free optical biosensor for ligand-directed functional selectivity acting on beta(2) adrenoceptor in living cells. FEBS Lett 582: 558-564.
17. Fang Y, Li GG, Peng J (2005). Optical biosensor provides insights for bradykinin B(2) receptor signaling in A431 cells. FEBS Lett 579: 6365-6374.
18. Ferrie AM, Sun H, Fang Y (2011). Label-free integrative pharmacology on-target of drugs at the beta(2)-adrenergic receptor. Sci Rep 1: 33.
19. Ferrie AM, Wang C, Deng H, Fang Y (2013). A label-free optical biosensor with microfluidics identifies an intracellular signalling wave mediated through the beta2-adrenergic receptor. Integr Biol 5: 1253-1261.
20. Fu Q, Chen X, Xiang YK (2013). Compartmentalization of beta-adrenergic signals in cardiomyocytes. Trends Cardiovasc Med 23: 250-256.
21. Goral V, Jin Y, Sun H, Ferrie AM, Wu Q, Fang Y (2011). Agonist-directed desensitization of the beta2-adrenergic receptor. PLoS ONE 6: e19282.
22. Gustafsson AB, Brunton LL (2000). beta-adrenergic stimulation of rat cardiac fibroblasts enhances induction of nitric-oxide synthase by interleukin-1beta via message stabilization. Mol Pharmacol 58: 1470-1478.
23. Irannejad R, Tomshine JC, Tomshine JR, Chevalier M, Mahoney JP, Steyaert J, et al. (2013). Conformational biosensors reveal GPCR signalling from endosomes. Nature 495: 534-538.
24. Jaffre F, Friedman AE, Hu Z, Mackman N, Blaxall BC (2012). beta-adrenergic receptor stimulation transactivates protease-activated receptor 1 via matrix metalloproteinase 13 in cardiac cells. Circulation 125: 2993-3003.
25. Janssens K, Boussemaere M, Wagner S, Kopka K, Denef C (2008). Beta1-adrenoceptors in rat anterior pituitary may be constitutively active. Inverse agonism of CGP 20712A on basal 3′, 5′-cyclic adenosine 5′-monophosphate levels. Endocrinology 149: 2391-2402.
26. Kim J, Eckhart AD, Eguchi S, Koch WJ (2002). Beta-adrenergic receptor-mediated DNA synthesis in cardiac fibroblasts is dependent on transactivation of the epidermal growth factor receptor and subsequent activation of extracellular signal-regulated kinases. J Biol Chem 277: 32116-32123.
27. Kim KS, Abraham D, Williams B, Violin JD, Mao L, Rockman HA (2012). beta-Arrestin-biased AT1R stimulation promotes cell survival during acute cardiac injury. Am J Physiol Heart Circ Physiol 303: H1001-H1010.
28. Kirchhausen T, Macia E, Pelish HE (2008). Use of dynasore, the small molecule inhibitor of dynamin, in the regulation of endocytosis. Methods Enzymol 438: 77-93.
29. Lamyel F, Warnken-Uhlich M, Seemann WK, Mohr K, Kostenis E, Ahmedat AS, et al. (2011). The beta2-subtype of adrenoceptors mediates inhibition of pro-fibrotic events in human lung fibroblasts. Naunyn-Schmiedeberg's Arch Pharmacol 384: 133-145.
30. Lau YH, Robinson RB, Rosen MR, Bilezikian JP (1980). Subclassification of beta-adrenergic receptors in cultured rat cardiac myoblasts and fibroblasts. Circ Res 47: 41-48.
31. Maudsley S, Pierce KL, Zamah AM, Miller WE, Ahn S, Daaka Y, et al. (2000). The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. J Biol Chem 275: 9572-9580.
32. Moore CA, Milano SK, Benovic JL (2007). Regulation of receptor trafficking by GRKs and arrestins. Annu Rev Physiol 69: 451-482.
33. Morse M, Sun H, Tran E, Levenson R, Fang Y (2013). Label-free integrative pharmacology on-target of opioid ligands at the opioid receptor family. BMC Pharmacol Toxicol 14: 17.
34. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J, et al. (2007). Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest 117: 2445-2458.
35. Peters MF, Vaillancourt F, Heroux M, Valiquette M, Scott CW (2010). Comparing label-free biosensors for pharmacological screening with cell-based functional assays. Assay Drug Dev Technol 8: 219-227.
36. Porter KE, Turner NA (2009). Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 123: 255-278.
37. Rocheville M, Martin J, Jerman J, Kostenis E (2013). Mining the potential of label-free biosensors for seven-transmembrane receptor drug discovery. Prog Mol Biol Transl Sci 115: 123-142.
38. Santiago JJ, Dangerfield AL, Rattan SG, Bathe KL, Cunnington RH, Raizman JE, et al. (2010). Cardiac fibroblast to myofibroblast differentiation in vivo and in vitro: expression of focal adhesion components in neonatal and adult rat ventricular myofibroblasts. Dev Dyn 239: 1573-1584.
39. Schrage R, Seemann WK, Klockner J, Dallanoce C, Racke K, Kostenis E, et al. (2013). Agonists with supraphysiological efficacy at the muscarinic M2 ACh receptor. Br J Pharmacol 169: 357-370.
40. Schroder R, Janssen N, Schmidt J, Kebig A, Merten N, Hennen S, et al. (2010). Deconvolution of complex G protein-coupled receptor signaling in live cells using dynamic mass redistribution measurements. Nat Biotechnol 28: 943-949.
41. Schroder R, Schmidt J, Blattermann S, Peters L, Janssen N, Grundmann M, et al. (2011). Applying label-free dynamic mass redistribution technology to frame signaling of G protein-coupled receptors noninvasively in living cells. Nat Protoc 6: 1748-1760.
42. Stallaert W, Dorn JF, van der Westhuizen E, Audet M, Bouvier M (2012). Impedance responses reveal beta(2)-adrenergic receptor signaling pluridimensionality and allow classification of ligands with distinct signaling profiles. PLoS ONE 7: e29420.
43. Taira CA, Monczor F, Hocht C (2010). Measurement of inverse agonism in beta-adrenoceptors. Methods Enzymol 485: 37-60.
44. Tilley DG (2011). G protein-dependent and G protein-independent signaling pathways and their impact on cardiac function. Circ Res 109: 217-230.
45. Tilley DG, Kim IM, Patel PA, Violin JD, Rockman HA (2009). beta-Arrestin mediates beta1-adrenergic receptor-epidermal growth factor receptor interaction and downstream signaling. J Biol Chem 284: 20375-20386.
46. Tilley DG, Nguyen AD, Rockman HA (2010). Troglitazone stimulates beta-arrestin-dependent cardiomyocyte contractility via the angiotensin II type 1A receptor. Biochem Biophys Res Commun 396: 921-926.
47. Tran E, Sun H, Fang Y (2012). Dynamic mass redistribution assays decode surface influence on signaling of endogenous purinergic P2Y receptors. Assay Drug Dev Technol 10: 37-45.
48. Turner NA, Porter KE, Smith WH, White HL, Ball SG, Balmforth AJ (2003). Chronic beta2-adrenergic receptor stimulation increases proliferation of human cardiac fibroblasts via an autocrine mechanism. Cardiovasc Res 57: 784-792.
49. Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, et al. (2010). Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335: 572-579.
50. Yin F, Lu ZZ, Han QD, Zhang YY (2003). Expression of beta2-adrenergic receptor and its effect on the proliferation of neonatal rat cardiac fibroblasts. Sheng Li Xue Bao 55: 251-254.
51. Zhang JH, Chung TD, Oldenburg KR (1999). A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4: 67-73.